A SECRET WEAPON FOR SEVITERONEL TNBC

Similar to TNBC, the position of AR while in the administration of estrogen receptor-beneficial (ER+) breast cancer is a place of Energetic study. AR is expressed in up to 90% of ER+ tumors and preclinical data indicates that AR expression is related to resistance to both of those tamoxifen and aromatase inhibitors in ER+ cell strains [14–16]. Th